リウマチ治療薬の世界市場レポート 2025年

リウマチ治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.8％で538億8,000万米ドルに成長します。予測期間の成長は、個別化医療アプローチへのシフト、リウマチ領域におけるバイオシミラーの採用増加、研究開発投資の増加、デジタルヘルス技術の統合、新規治療に対する規制当局の承認などに起因すると考えられます。予測期間における主な動向としては、遠隔医療および遠隔モニタリングソリューションの成長、特定のリウマチ疾患に対する標的治療の拡大、患者中心のケアモデルの重視、モノクローナル抗体以外の生物学的製剤治療の拡大、価値ベースの価格設定モデルの採用などが挙げられます。

自己免疫疾患の有病率の増加は、リウマチ治療薬市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が誤って体内組織を攻撃することで発症します。これらの疾患の増加は、認知度の向上や診断法の改善とともに、遺伝的、環境的、ライフスタイル的要因に起因しています。リウマチ治療薬は、こうした免疫反応による炎症を管理し、症状を緩和し、関節や組織の損傷を防ぐために不可欠です。例えば、オーストラリアの政府機関であるAustralian Institute of Health and Welfareが2024年6月に発表した報告書によると、2022年には人口の2.0％にあたる約51万4,000人のオーストラリア人が関節リウマチに罹患していると推定されています。この疾患は、2023年には全疾患負担の2.0%、全筋骨格系疾患の負担の16%を占める。その結果、自己免疫疾患の有病率の上昇がリウマチ治療薬市場を押し上げています。

リウマチ治療薬市場の主要企業は、治療効果と患者の利便性を向上させるため、静脈内投与製剤などの革新的なソリューションを開発しています。静脈内投与製剤は、注射針やカテーテルを介して静脈に直接薬剤を投与するものです。例えば、2023年10月、スイスの製薬会社であるノバルティスAGは、米国食品医薬品局（FDA）がコセンティックスの静注製剤を承認したと発表しました。コセンティックスのこのバージョンは、成人の乾癬性関節炎（PsA）、強直性脊椎炎（AS）、非放射線性軸索脊椎関節炎（nr-axSpA）の治療薬として承認されています。本薬は、インターロイキン-17A（IL-17A）を特異的に標的として阻害することにより作用し、これらの疾患に対して使用可能な唯一の非腫瘍壊死因子α（TNF-a）静注療法です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界リウマチ治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のリウマチ治療薬市場：成長率分析
• 世界のリウマチ治療薬市場の実績：規模と成長, 2019-2024
• 世界のリウマチ治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界リウマチ治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のリウマチ治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 疾患修飾性抗リウマチ薬
• 非ステロイド性抗炎症薬
• コルチコステロイド
• 尿酸薬
• その他の薬物クラス
• 世界のリウマチ治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のリウマチ治療薬市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節リウマチ
• 変形性関節症
• 痛風
• 乾癬性関節炎
• 強直性脊椎炎
• その他の疾患の適応症
• 世界のリウマチ治療薬市場疾患修飾性抗リウマチ薬（DMARD）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来の合成DMARD
• 生物学的DMARD
• 標的合成DMARD
• 世界のリウマチ治療薬市場非ステロイド性抗炎症薬（NSAIDs）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• COX-2阻害剤
• 従来のNSAIDs
• 世界のリウマチ治療薬市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口コルチコステロイド
• 注射用コルチコステロイド
• 局所コルチコステロイド
• 世界のリウマチ治療薬市場尿酸薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尿酸値低下剤
• 尿酸排泄促進剤
• ペグロチカーゼ
• 世界のリウマチ治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制剤
• 生物学的療法
• 鎮痛剤

第7章 地域別・国別分析

• 世界のリウマチ治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のリウマチ治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• リウマチ治療薬市場：競合情勢
• リウマチ治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Janssen Biotech
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals
• UCB S.A.
• Galapagos NV（GLPG）

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• リウマチ治療薬市場2029：新たな機会を提供する国
• リウマチ治療薬市場2029：新たな機会を提供するセグメント
• リウマチ治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Rheumatology therapeutics include treatments designed to manage and alleviate the symptoms of rheumatic diseases such as arthritis, lupus, and gout. These therapies encompass medications such as anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), and biologics, as well as physical therapy and lifestyle changes. The primary objective is to reduce inflammation, control pain, and enhance patients' quality of life.

The main categories of rheumatology therapeutics are disease-modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs, and others. Disease-modifying antirheumatic drugs (DMARDs) are a class of medications intended to slow or alter the underlying disease process in rheumatoid arthritis and other autoimmune conditions, rather than merely alleviating symptoms. These drugs are available through hospital pharmacies, retail pharmacies, and online pharmacies and are used to treat conditions such as rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, ankylosing spondylitis, and others.

The rheumatology therapeutics market research report is one of a series of new reports from The Business Research Company that provides rheumatology therapeutics market statistics, including rheumatology therapeutics industry global market size, regional shares, competitors with a rheumatology therapeutics market share, detailed rheumatology therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatology therapeutics industry. This rheumatology therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rheumatology therapeutics market size has grown strongly in recent years. It will grow from $42.4 billion in 2024 to $44.61 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to the rising prevalence of rheumatologic disorders, increasing the aging population globally, growing awareness about treatment options, advancements in biological therapies, and expansion of healthcare access in emerging markets.

The rheumatology therapeutics market size is expected to see steady growth in the next few years. It will grow to $53.88 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to the shift towards personalized medicine approaches, rising adoption of biosimilars in rheumatology, increasing investment in research and development, integration of digital health technologies, and regulatory approvals for novel therapies. Major trends in the forecast period include growth in telemedicine and remote monitoring solutions, expansion of targeted therapies for specific rheumatic conditions, emphasis on patient-centric care models, expansion of biologic treatments beyond monoclonal antibodies, and adoption of value-based pricing models.

The increasing prevalence of autoimmune diseases is anticipated to drive the growth of the rheumatology therapeutics market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues. The rise in these diseases is attributed to genetic, environmental, and lifestyle factors, alongside increased awareness and improved diagnostics. Rheumatology therapeutics are essential for managing inflammation, alleviating symptoms, and preventing joint and tissue damage caused by these immune responses. For example, a June 2024 report from the Australian Institute of Health and Welfare, an Australian government agency, estimated that around 514,000 Australians, or 2.0% of the population, were living with rheumatoid arthritis in 2022. This condition accounted for 2.0% of the total disease burden and 16% of the burden for all musculoskeletal conditions in 2023. Consequently, the rising prevalence of autoimmune diseases is boosting the rheumatology therapeutics market.

Leading companies in the rheumatology therapeutics market are developing innovative solutions, such as intravenous (IV) formulations, to improve treatment efficacy and patient convenience. An intravenous (IV) formulation involves administering medication directly into a vein via a needle or catheter. For instance, in October 2023, Novartis AG, a Swiss pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved an IV formulation of Cosentyx. This version of Cosentyx is approved for treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It works by specifically targeting and inhibiting interleukin-17A (IL-17A) and is the only non-tumor necrosis factor alpha (TNF-a) IV treatment available for these conditions.

In February 2024, Alfasigma S.p.A., an Italian pharmaceutical company, acquired the Jyseleca (filgotinib) business from Galapagos NV for $184.54 million. This acquisition has expanded Alfasigma's product portfolio with an innovative pharmaceutical targeting gastrointestinal and rheumatological treatments. Additionally, it strengthens Alfasigma's presence in European markets by integrating Jyseleca's business, including marketing authorizations across Europe and the UK, and operations in commercialization, medical affairs, and development. Galapagos NV is a Belgian manufacturer of rheumatology therapeutics.

Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Janssen Biotech, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Galapagos NV (GLPG), Genentech Inc.

North America was the largest region in the rheumatology therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rheumatology therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rheumatology therapeutics market consists of revenues earned by entities by providing services such as diagnostic services, telemedicine, rehabilitation services, and lifestyle and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The rheumatology therapeutics market also includes sales of biologic response modifiers, janus kinase (JAK) inhibitors, analgesics, and immunosuppressants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rheumatology Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rheumatology therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rheumatology therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rheumatology therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs; Nonsteroidal Anti-Inflammatory Drugs; Corticosteroids; Uric Acid Drugs; Other Drugs Classes
• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 3) By Disease Indication: Rheumatoid Arthritis; Osteoarthritis; Gout; Psoriatic Arthritis; Ankylosing Spondylitis; Other Disease Indications
• Subsegments:
• 1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs; Biologic DMARDs; Targeted Synthetic DMARDs
• 2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors; Traditional NSAIDs
• 3) By Corticosteroids: Oral Corticosteroids; Injectable Corticosteroids; Topical Corticosteroids
• 4) By Uric Acid Drugs: Uric Acid Lowering Agents; Uricosuric Agents; Pegloticase
• 5) By Other Drug Classes: Immunosuppressants; Biologic Therapies; Analgesics
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rheumatology Therapeutics Market Characteristics

3. Rheumatology Therapeutics Market Trends And Strategies

4. Rheumatology Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Rheumatology Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rheumatology Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rheumatology Therapeutics Market Growth Rate Analysis
• 5.4. Global Rheumatology Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rheumatology Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rheumatology Therapeutics Total Addressable Market (TAM)

6. Rheumatology Therapeutics Market Segmentation

• 6.1. Global Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Disease Modifying Anti-Rheumatic Drugs
• Nonsteroidal Anti-Inflammatory Drugs
• Corticosteroids
• Uric Acid Drugs
• Other Drug Classes
• 6.2. Global Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.3. Global Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Osteoarthritis
• Gout
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Other Disease Indications
• 6.4. Global Rheumatology Therapeutics Market, Sub-Segmentation Of Disease Modifying Anti-Rheumatic Drugs (DMARDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Synthetic DMARDs
• Biologic DMARDs
• Targeted Synthetic DMARDs
• 6.5. Global Rheumatology Therapeutics Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• COX-2 Inhibitors
• Traditional NSAIDs
• 6.6. Global Rheumatology Therapeutics Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Corticosteroids
• Injectable Corticosteroids
• Topical Corticosteroids
• 6.7. Global Rheumatology Therapeutics Market, Sub-Segmentation Of Uric Acid Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Uric Acid Lowering Agents
• Uricosuric Agents
• Pegloticase
• 6.8. Global Rheumatology Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Biologic Therapies
• Analgesics

7. Rheumatology Therapeutics Market Regional And Country Analysis

• 7.1. Global Rheumatology Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rheumatology Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rheumatology Therapeutics Market

• 8.1. Asia-Pacific Rheumatology Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rheumatology Therapeutics Market

• 9.1. China Rheumatology Therapeutics Market Overview
• 9.2. China Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rheumatology Therapeutics Market

• 10.1. India Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rheumatology Therapeutics Market

• 11.1. Japan Rheumatology Therapeutics Market Overview
• 11.2. Japan Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rheumatology Therapeutics Market

• 12.1. Australia Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rheumatology Therapeutics Market

• 13.1. Indonesia Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rheumatology Therapeutics Market

• 14.1. South Korea Rheumatology Therapeutics Market Overview
• 14.2. South Korea Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rheumatology Therapeutics Market

• 15.1. Western Europe Rheumatology Therapeutics Market Overview
• 15.2. Western Europe Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rheumatology Therapeutics Market

• 16.1. UK Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rheumatology Therapeutics Market

• 17.1. Germany Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rheumatology Therapeutics Market

• 18.1. France Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rheumatology Therapeutics Market

• 19.1. Italy Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rheumatology Therapeutics Market

• 20.1. Spain Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rheumatology Therapeutics Market

• 21.1. Eastern Europe Rheumatology Therapeutics Market Overview
• 21.2. Eastern Europe Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rheumatology Therapeutics Market

• 22.1. Russia Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rheumatology Therapeutics Market

• 23.1. North America Rheumatology Therapeutics Market Overview
• 23.2. North America Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rheumatology Therapeutics Market

• 24.1. USA Rheumatology Therapeutics Market Overview
• 24.2. USA Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rheumatology Therapeutics Market

• 25.1. Canada Rheumatology Therapeutics Market Overview
• 25.2. Canada Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rheumatology Therapeutics Market

• 26.1. South America Rheumatology Therapeutics Market Overview
• 26.2. South America Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rheumatology Therapeutics Market

• 27.1. Brazil Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rheumatology Therapeutics Market

• 28.1. Middle East Rheumatology Therapeutics Market Overview
• 28.2. Middle East Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rheumatology Therapeutics Market

• 29.1. Africa Rheumatology Therapeutics Market Overview
• 29.2. Africa Rheumatology Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rheumatology Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rheumatology Therapeutics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rheumatology Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Rheumatology Therapeutics Market Competitive Landscape
• 30.2. Rheumatology Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Rheumatology Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. Novartis AG
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Gilead Sciences Inc.
• 31.10. Janssen Biotech
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Biogen Inc.
• 31.13. Vertex Pharmaceuticals
• 31.14. UCB S.A.
• 31.15. Galapagos NV (GLPG)

32. Global Rheumatology Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rheumatology Therapeutics Market

34. Recent Developments In The Rheumatology Therapeutics Market

35. Rheumatology Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Rheumatology Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rheumatology Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rheumatology Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer